Core Viewpoint - LifeVantage Corporation reported strong financial results for the third fiscal quarter of 2025, with a significant increase in revenue and profitability, driven by robust demand for its products and international expansion efforts [4][5]. Financial Performance - Revenue for the third quarter ended March 31, 2025, was $58.4 million, representing a 21.1% increase year-over-year. Excluding foreign currency fluctuations, revenue increased by 22.1% [5][9]. - Gross profit for the quarter was $47.3 million, or 81.0% of revenue, compared to 78.9% in the same period of fiscal 2024, attributed to a favorable product sales mix and reduced inventory costs [6]. - Adjusted EBITDA rose by 27% to $6.4 million from $5.1 million a year ago [9][12]. - Net income for the quarter was $3.5 million, or $0.26 per diluted share, compared to $1.7 million, or $0.13 per diluted share, in the prior year [11][9]. Regional Performance - Revenue in the Americas increased by 29.5%, with a notable 31.4% rise in the United States. Conversely, revenue in the Asia/Pacific & Europe region decreased by 7.2%, with a constant currency decline of approximately 4.7% [5][9]. Operational Highlights - The company launched its Evolve Compensation Plan in several Asian markets and introduced the MindBody GLP-1 System™ in multiple international regions, indicating a strategic focus on global market expansion [4]. - Active Independent Consultants increased by 6.1% to 52,000, with a 12.9% rise in the Americas, while the Asia/Pacific & Europe region saw a decline of 5.6% [32]. Balance Sheet and Liquidity - Cash and cash equivalents as of March 31, 2025, were $22.5 million, up from $16.9 million at the end of June 2024, with no debt outstanding [13]. - The company generated $10.8 million in cash from operations during the first nine months of fiscal 2025, compared to $9.6 million in the same period of fiscal 2024 [13]. Shareholder Returns - LifeVantage declared a cash dividend of $0.045 per common share, scheduled for payment on June 13, 2025 [15]. Fiscal Year Guidance - The company expects revenue for fiscal year 2025 to be in the range of $228 million to $235 million, with adjusted EBITDA guidance of $21 million to $24 million and adjusted earnings per share between $0.72 and $0.88 [16].

Core Insights - LifeVantage Corporation successfully concluded its annual Global Convention in Salt Lake City, attended by over 2,000 Independent Consultants from around the world, focusing on business updates, product announcements, and training initiatives [1][2] Group 1: Product Launch and Expansion - The MindBody GLP-1 System™, previously available in the U.S. and Japan, is now launched for consumers in Europe, Mexico, Thailand, Australia, and New Zealand, marking a significant step in LifeVantage's global expansion [2] - Clinical study results revealed that both the MindBody GLP-1 System™ and MB System™ increased GLP-1 levels in the body by over 200 percent on average [3] Group 2: Sales Incentives and Events - The Drive ERA Q2 Sales Incentive doubles the bonus for Consultants reaching Senior Consultant 1 rank through customer enrollment and retention within the first three months [4] - LifeVantage announced the Executive Destination Trip for North American and European markets will take place in Thailand in 2026, along with the Activate Virtual Event on July 12 and the U.S. Momentum Academy scheduled for October 23-25 in Dallas, Texas [5] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, offering a range of health and wellness products designed to activate optimal health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and AXIO® nootropic energy drink mixes [6]

Company Overview - LifeVantage Corporation (Nasdaq: LFVN) is a leading health and wellness company focused on activating optimal health processes at the cellular level [1] - The company specializes in nutrigenomics, which studies how nutrition and naturally occurring compounds can unlock genetic health [4] - LifeVantage offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] Upcoming Financial Results - LifeVantage will release its financial results for the third quarter ended March 31, 2025, after the stock market closes on May 6, 2025 [1] - A conference call for investors is scheduled for 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day [1] Investor Participation - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and can be accessed until May 20, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days for later access [3]